摘要
麻杏石甘汤起源于《伤寒论》,是新冠疫情使用的中药基础方剂,在抗疫中发挥极其重要的作用。针对的病机是外邪郁闭、痰热阻肺,用于治疗肺热喘嗽与温热类疾病,在治疗呼吸道感染、肺炎、慢性阻塞性肺疾病(COPD)、支气管哮喘等疾病疗效显著。临床应用治疗哮喘中生石膏多为麻黄的4倍,麻黄最佳剂量为24 g;肺炎的治疗中石膏用量多为麻黄的5倍,麻杏石甘汤发挥抗病毒、抗炎等药理作用的相关靶点包括白细胞介素-6(IL-6)、IL-17、肿瘤坏死因子(TNF)、促分裂原活化的蛋白激酶(MAPK)等。临床治疗疾病中与免疫调控(包括成熟的T淋巴细胞CD3^(+)、CD4^(+)、CD8^(+)等)密切相关。现对麻杏石甘汤的古代文献、治疗肺系疾病量效、药理作用、现代基础及临床研究进行概述。总结现有研究不足,在以后的研究应侧重于中药复方指纹图谱、药效机制、标准汤剂和治疗疾病疗效评价的标准化等方面开展。
Maxing Shigan Decoction,derived from Treatise on Cold Damage(Shang Han Lun)is the basic traditional Chinese medicine(TCM)prescription for the treatment of COVID-19,which plays an extremely important role in resisting the epidemic.It is used to treat asthma due to lung heat or warm febrile diseases with the pathogenesis of stagnation and block of external pathogens,phlegm-heat obstructing lung.Maxing Shigan Decoction is effective in treating respiratory infection,pneumonia,chronic obstructive pulmonary disease(COPD),bronchial asthma and other diseases.In the treatment of asthma,the clinical dose of Gypsum Filrosum is 4 times that of Herba Ephedrae(the optimal dose is 24 g).While in the treatment of pneumonia,the amount of Gypsum Filrosum is mostly 5 times that of Herba Ephedrae.The targets involving in the antiviral and anti-inflammatory pharmacological effects of Maxing Shigan Decoction include interleukin 6(IL-6),interleukin 17(IL-17),tumor necrosis factor(TNF),and mitogen-activated protein kinase(MAPK),and the prescription is closely related to immune regulation(including mature T lymphocytes CD3^(+),CD4^(+),and CD8^(+))in clinical treatment of diseases.This paper reviewed the ancient literature on Maxing Shigan Decoction,the dose-response relationship in treating lung diseases,pharmacological action,modern basis and clinical research.The shortcomings of the existing research were summarized,and the paper proposed that future research should focus on the fingerprint of TCM compounds,pharmacodynamic mechanism,standard decoction and efficacy evaluation standards in the treatment of diseases.
作者
马媛虹
程淼
李长安
王明哲
于会勇
徐红日
郭雨菲
黄廷轩
王成祥
MA Yuanhong;CHENG Miao;LI Chang′an;WANG Mingzhe;YU Huiyong;XU Hongri;GUO Yufei;HUANG Tingxuan;WANG Chengxiang(Beijing University of Chinese Medicine,Beijing 100029,China;Beijing University of Chinese Medicine Third Affiliated Hospital,Beijing 100029,China;Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China)
出处
《世界中医药》
CAS
2023年第18期2696-2700,共5页
World Chinese Medicine
基金
国家自然科学基金项目(82074389)。
关键词
麻杏石甘汤
辅助治疗
肺系疾病
古今文献
量效药理
基础实验
临床应用
研究概述
Maxing Shigan Decoction
Auxiliary treatment
Lung diseases
Ancient and modern literature
Dose-response pharmacology
Basic experiment
Clinical application
Overview of research
